WE Barlow

SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer

Georgiana K. Ellis, WE Barlow, Christy Russell et al. · Journal of Clinical Oncology · 2006 · 34 citations

Medicine, Oncology, Pharmacotherapy +16

SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less.

Ana M. González-Angulo, WE Barlow, JR Gralow et al. · Journal of Clinical Oncology · 2011 · 27 citations

Medicine, Oncology, Breast Oncology +15

Abstract OT1-02-04: SWOG S1418/NRG -BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with <u>&amp;gt;</u> 1 cm residual invasive cancer or positive lymph nodes (&amp;gt;pN1mic) after neoadjuvant chemotherapy

Lajos Pusztai, WE Barlow, PA Ganz et al. · Cancer Research · 2018 · 24 citations

Medicine, Oncology, Breast Oncology +16

Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

JB Smerage, WE Barlow, DF Hayes et al. · Cancer Research · 2013 · 14 citations

Medicine, Oncology, Breast Oncology +14

S1-1: A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226.

Mehta Rs, WE Barlow, KS Albain et al. · Cancer Research · 2011 · 13 citations

Medicine, Oncology, Pharmacology +16